лÌñ
лÌñ£¬1990Äê»ñҽѧ²©Ê¿£¬¶þ¼¶明升体育¡¢²©µ¼¡£ÏµÖйúҽѧ¿ÆѧԺѧ²¿Î¯Ô±£¬Ó¢¹ú»Ê¼Ò»¯Ñ§»á»áÊ¿£¬¹úÎñÔºÌØÊâ½òÌùר¼Ò¡¢¹ú¼Ò᪻ÆѧÕß¡¢Õã½Ê¡Ìؼ¶×¨¼Ò¡£¹ú¼ÒÒ»Á÷±¾¿Æרҵ£¨Ò©Ñ§£©¸ºÔðÈË£¬ÖÎδ²¡Ó뽡¿µ¹ÜÀí¹ú¼Ò¸ßˮƽÖصãѧ¿Æ´øÍ·ÈË£¬Õã½Ê¡éÏãÏ©¿¹°©ÐÂÒ©Ñо¿ÖصãʵÑéÊÒÖ÷ÈΣ¬Õã½Ê¡ÖÐÒ©×ÊÔ´¿ª·¢ÓëÓ¦Óù¤³ÌÑо¿ÖÐÐÄÖ÷ÈΣ¬Õã½Ê¡Ò©Ñ§ÊýÖÇÐéÄâ½ÌÑÐÊÒÖ÷ÈΣ¬Õã½Ê¡Ò©Ñ§ÊýÖÇʵÑé½Ìѧʾ·¶ÖÐÐÄÖ÷ÈΡ£¼æÈÎÖйú¿¹°©Ð»á³£ÎñÀíÊ¡¢ÖÐÎ÷Ò½ÕûºÏÖ×Áöѧרί»á´´Ê¼Ö÷ÈÎίԱ¡¢ÖÐÎ÷Ò½ÕûºÏ¿ØÁöÐÂҩרί»áÖ÷ÈÎίԱ£¬ÖйúÖÐÎ÷Ò½½áºÏѧ»á³£ÎñÀíÊ£¬ÊÀ½çÖÐÒ½Ò©ÁªºÏ»áÖ×Áö·Ö»á¸±»á³¤£¬Õã½Ê¡¿¹°©Ð»áÕûºÏÖ×Áöרί»áÖ÷ÈΡ£¡¶ÊÀ½çÖÐÎ÷Ò½½áºÏÔÓÖ¾¡·¸±Ö÷±à¡¢¡¶ÖйúʵÑé·½¼ÁѧÔÓÖ¾¡·¸±Ö÷±à¡¢¡¶ÖÐÒ½Ö×ÁöѧÔÓÖ¾¡·¸±Ö÷±à¡£
´ÓÊÂÖÐÒ©ÌìȻҩÎïÑз¢¡¢ÖÐÎ÷Ò½½áºÏ¡¢Ö¬ÖÊÌåÄÉÃ×ÖƼÁ¡¢ÂÌÉ«»¯Ñ§µÈÒ½½ÌÑÐÓëת»¯¹¤×÷40¶àÄ꣬´´ÐÂÌá³öÖÐÎ÷½áºÏ¡°·Ö×ÓÅäÎ顱ÀíÂÛÑз¢ÐÂÒ©¼°ÖÎÁÆ°©Ö¢£¬Ñз¢³É¹¦ÎÒ¹úÔ´´·Ö×ÓÅäÎ鿹°©ÐÂÒ©éÏãÏ©Ö¬ÖÊÌ壨éÏãÏ©Èé×´×¢ÉäÒº¡¢éÏãÏ©¿Ú·þÈ飩µÈÐÂÒ©¡£ÒÔµÚÒ»Íê³ÉÈË»ñ¹ú¼Ò¿Æ¼¼½ø²½¶þµÈ½±2Ïî¡¢Öйú·¢Ã÷רÀû½ð½±2Ïî¡¢½ÌÓý²¿¸ßУÓÅÐã¿ÆÑгɹûÒ»µÈ½±3ÏÈÙ»ñºÎÁººÎÀû¿Æ¼¼½±¡¢Îâ½×ƽҽҩ´´Ð½±¡¢Ê÷À¼Ò½Ñ§½±¡¢Öйúҩѧ·¢Õ¹½±´´ÐÂÒ©ÎïÍ»³ö³É¾Í½±¡¢º¼ÖÝÊпƼ¼´´ÐÂÌرð¹±Ï×½±µÈ¡£ÔÚSci Transl Med£¬PNAS£¬JACS£¬Matter£¬Angewandte Chemie£¬Chem Soc Rev£¬Adv Mater£¬Nat CommunµÈ·¢±íѧÊõÂÛÎÄ200Óàƪ£»°®Ë¼Î¨¶û³ö°æ¡¶Elemene Antitumor Drugs: Molecular Compatibility Theory and its Applications in New Drug Development and Clinical Practice¡·¡¢¡¶éÏãÏ©Ö¬ÖÊÌåÖÐÎ÷Ò½½áºÏ¿¹Ö×Áö»ù´¡ÓëÁÙ´²Ñо¿¡ª¡ª·Ö×ÓÅäÎéÑз¢¿¹°©ÐÂÒ©ÀíÂÛÓëʵ¼ù¡·¡¢¡¶ÁÙ´²Ò©Àíѧ¡·£¨°¸Àý°æ¹æ»®½Ì²Ä£©¡¢¡¶Ò©Îﻯѧ¡·£¨ÐÂÒ©Ñз¢°æ¹æ»®½Ì²Ä£©¡¢¡¶Ò©ÎïÑз¢»ù±¾ÔÀí¡·¡¢¡¶³É¹¦Ò©ÎïÑз¢¡·¡¢¡¶ÔçÆÚÒ©Î↑·¢¡·¡¢¡¶ÀàÒ©ÐÔ¡·µÈרÖø¡¢½Ì²ÄºÍÒëÖø20Óಿ¡£»ñÊÚȨÖйú¡¢Å·ÃÀ¡¢ÈÕ±¾µÈ¹ú·¢Ã÷רÀû50¶àÏî¡£
ÁªÏµÓÊÏ䣺tianxie@hznu.edu.cn
´ú±íÐԳɹû£¨¿Éº¬³Ðµ£ÏîÄ¿¡¢·¢±íÂÛÎÄ¡¢ÂÛÖø¡¢»ñ½±µÈ£©
£¨Ò»£©²¿·Ö³Ðµ£ÏîÄ¿
1. ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÖصãÏîÄ¿£º»ùÓÚÑ֤ҽѧ֤¾ÝµÄÖÐÒ©éÏãÏ©ÖÎÁƷΰ©°Ð±ê·¢ÏÖ¼°ÄæתTKIÄÍÒ©»úÖÆ̽¾¿
2.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£º»ùÓÚLncRNAH19ÓÕµ¼µÄϸ°û×ÔÊÉ̽ÌÖéÏãÏ©ÄæתNSCLC¼ª·ÇÌæÄáÄÍÒ©µÄ·Ö×Ó»úÖÆÑо¿
3.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£º³¬µÍÎÂ΢²¨¸¨Öú¿¹°©ÌìÈ»²úÎïéÏãÏ©µÄ¹ÑëÄÐÞÊÎÑо¿
4.¹ú¼Ò¸ß¼¼Êõ²úÒµ»¯Ê¾·¶¹¤³ÌÏîÄ¿£º±ôΣÕäÏ¡Ò©²ÄÌúƤʯõúÈ˹¤·±Óý¼°ÌúƤ·ã¶·ÏµÁÐÖÐÒ©ÖƼÁ¸ß¼¼Êõ²úÒµ»¯Ê¾·¶¹¤³Ì
5.¹ú¼ÒÖØ´ó¿Æ¼¼×¨ÏÌìÈ»¿¹Ö×ÁöÒ©éÏãϩעÉäÒºÃð¾úF0¼°ÔÓÖÊ¿ØÖƼ¼Êõ
6.¹ú¼Ò¸ß¼¼Êõ²úÒµ»¯Ê¾·¶¹¤³ÌÏîÄ¿£ºéÏãϩϵÁп¹Ö×ÁöÖ²ÎïÒ©¸ß¼¼Êõ²úÒµ»¯Ê¾·¶¹¤³Ì
7.Õã½Ê¡ÖØ´ó¿Æ¼¼×¨ÏÖÎÁÆ×Ïɼ´¼ÄÍÒ©Ö×ÁöµÄÐÂÒ©¿¨°ÍËûÈüÑôÀë×ÓÈáÐÔÈé¼ÁÑз¢
8.Õã½Ê¡ÖØ´ó¿Æ¼¼×¨Ï³£¼û¶ñÐÔÖ×Áö·öÕýìîа·¨ÁÙ´²Ó¦ÓÃм¼ÊõÑо¿-éÏãÏ©Ö¬ÖÊÌå·öÕýìîа·¨ÄæתÄÍÒ©·Î°©Ð¼¼ÊõÑо¿
9.Õã½Ê¡ÖØ´ó¿Æ¼¼´´ÐÂרÏËûÍ¡ÀàϵÁÐÔÁÏÒ©ÂÌÉ«ºÏ³É¼¼Êõ¼¯³ÉºÍʾ·¶
10.ºáÏò¿ÎÌ⣺éÏãÏ©×÷Óðб귢ÏÖ¼°Äæת·Ö×Ó°ÐÏòÒ©£¨TKI£©ÄÍÒ©»úÖÆÑо¿
£¨¶þ£©²¿·Ö·¢±íÂÛÎÄ£¨½üÄêÀ´´ú±íÐÔÂÛÎÄ10ƪ£©
1. 1.Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer PNAS,2022,7,119:e2112696119
2.Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes -deficient cancers to mTOR inhibition Science Translational Medcine£¬2019,523,11
3.Stanene-based nanosheets for ¦Â-Elemene delivery and ultrasound-mediated combination cancer therapy Angewandte Chemie-International Edition, 2021,13,60.
4.Arsenene Nanodots with Selective Killing Effects and their Low-Dose Combination with ?-Elemene for Cancer Therapy Advanced Materials£¬2021,37,33
5.Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy ACS Nano, 2019,1,13: 357-370
6.Germanene-based theranostic materials for surgical adjuvant treatment: inhibiting tumor recurrence and wound infection Matter, 2020,1,3:127-144
7.Pnictogens in medicinal chemistry: evolution from erstwhile drugs to emerging layered photonic nanomedicine Chemical Society Reviews, 2021,4,50: 2260-2279.
8.Ultrasound mediated therapy: recent progress and challenges in nanoscience Nano Today,2020 35:100949
9.Nanoheterojunction-mediated thermoelectric strategy for cancer surgical adjuvant treatment and ¦Â-elemene combination therapy Advanced Materials, 2022:2207391
10.Elemene Hydrogel Modulates the Tumor Immune Microenvironment for Enhanced Treatment of Postoperative Cancer Recurrence and Metastases,JACS£¬December,3,2024
£¨Èý£©²¿·ÖÂÛÖø£¨½üÄêÀ´´ú±íÐÔÂÛÖø10²¿£©
1.Tian Xie, et al, Elemene Antitumor Drugs: Molecular Compatibility Theory and its Applications in New Drug Development and Clinical Practice, Elsevier, 2022, USA
2.лÌñ, ³Ìº£²¨, µÈ, ¡¶éÏãÏ©Ö¬ÖÊÌ忹Ö×ÁöÖÐÎ÷Ò½½áºÏ»ù´¡ÓëÁÙ´²Ñо¿¡ª¡ª·Ö×ÓÅäÎéÑз¢¿¹°©ÐÂÒ©ÀíÂÛÓëʵ¼ù¡·, ÈËÃñÎÀÉú³ö°æÉç, 2019, ±±¾©.
3.°×ÈÊÈÊ£¨Ö÷Ò룩,лÌñ£¨Ö÷Éó£©,µÈ,¡¶Ò©Îï°Ðµã·¢ÏÖÓëÈ·Ö¤¡·£¬»¯Ñ§¹¤Òµ³ö°æÉ磬2024.
4.лСºì£¨Ö÷±à£©£¬Ð»Ìñ£¨Ö÷Éó£©,¡¶ÖÐÒ½È鲡ÍâÖΡ·£¬Õã½´óѧ³ö°æÉ磬2024.
5.лÌñ£¬ÎºÃô½Ü£¬µÈ£¬¡¶ÁÙ´²Ò©Àíѧ¡·£¬¿Æѧ³ö°æÉ磬2024£¬±±¾©.
6.°×ÈÊÈÊ£¨Ö÷±à£©,лÌñ£¨Ö÷Éó£©, ¡¶Ò©Îﻯѧ¡·, ¿Æѧ³ö°æÉç, 2024, ±±¾©.
7.ÀîÎÄÔË¡¢°×ÈÊÈÊ£¨Ö÷Ò룩, лÌñ£¨Ö÷Éó£©, µÈ, ¡¶Í¼½âÒ©Àíѧ¡·, ÈËÃñÎÀÉú³ö°æÉç, 2023, ±±¾©.
8.°×ÈÊÈÊ£¨Ö÷Ò룩, лÌñ£¨Ö÷Éó£©, µÈ, ¡¶Ò©ÎïÑз¢»ù±¾ÔÀí¡·µÚ2°æ, ¿Æѧ³ö°æÉç, 2023, ±±¾©.
9.ÕÔάÁ¼,лÌñ(Ö÷±à)£¬¡¶Ö²Îﻯѧ³É·ÖººÓ¢Ãû³Æ¼¯£¨ÉÏϲᣩ¡·£¬¿Æѧ³ö°æÉ磬2023£¬±±¾©.
10.°×ÈÊÈÊ£¨Ö÷Ò룩, лÌñ£¨Ö÷Éó£©, µÈ, ¡¶ÀàÒ©ÐÔ: ¸ÅÄî¡¢½á¹¹Éè¼ÆÓë·½·¨¡·, »¯Ñ§¹¤Òµ³ö°æÉç, 2021, ±±¾©.
£¨ËÄ£©²¿·Ö»ñ½±
1.¹ú¼Ò¿Æ¼¼½ø²½½±¶þµÈ½±£ºÐÂÐÍϡȱø×ÊÔ´Ñз¢Ìåϵ´´½¨¼°ÆäÔÚÒ½Ò©ÁìÓòÓ¦Ó㬵ÚÒ»Íê³ÉÈË
2.½ÌÓý²¿¿Æ¼¼½ø²½Ò»µÈ½±£ºÐÂÐÍϡȱø×ÊÔ´Ñз¢Ìåϵ´´½¨¼°ÆäÔÚÒ½Ò©ÁìÓòÓ¦Ó㬵ÚÒ»Íê³ÉÈË
3.¹ú¼Ò¿Æ¼¼½ø²½½±¶þµÈ½±£ºéÏãÏ©Ö¬ÖÊÌåϵÁаÐÏò¿¹°©ÌìȻҩÎï²úÒµ»¯¼¼Êõ¼°ÆäÓ¦Ó㬵ÚÒ»Íê³ÉÈË
4.½ÌÓý²¿¿Æ¼¼½ø²½Ò»µÈ½±£º½ð¸ÛéÏãϩϵÁп¹Ö×ÁöÖ²ÎïÒ©Ñо¿ÆäÓ¦Ó㬵ÚÒ»Íê³ÉÈË
5.½ÌÓý²¿¿Æ¼¼½ø²½Ò»µÈ½±£º±ôΣÕäÏ¡ÖÐÒ©ÌúƤʯõú»ôɽʯõú·±Óý¼¼Êõ¼°ÖÊÁ¿Ìåϵ´´½¨ÓëÍƹãÓ¦Ó㬵ÚÒ»Íê³ÉÈË
6.Öйú·¢Ã÷רÀû½ð½±£ºÒ»ÖÖ´ÓÎÂÓô½ðÖÐÖƱ¸¿¹°©Ò©éÏãÏ©µÄ·½·¨£¬µÚÒ»·¢Ã÷ÈË
7.Öйú·¢Ã÷רÀû½ð½±£ºÒ»ÖÖºê»ùÒò×éÀ´Ô´µÄÖ¬·¾Ã¸¡¢±àÂë»ùÒò¡¢ÔØÌå¡¢¹¤³Ì¾ú¼°ÔÚÒ¶»ÆËØÖƱ¸ÖеÄÓ¦Ó㬵ÚÒ»·¢Ã÷ÈË
8.ºÎÁººÎÀû¿Æѧ¼¼Êõ½±
9.Îâ½×ƽҽҩ´´Ð½±
10.Ê÷À¼Ò½Ñ§½±
11.Öйúҩѧ·¢Õ¹½±´´ÐÂÒ©ÎïÍ»³ö³É¾Í½±
12.ÖйúÖÐÎ÷Ò½½áºÏѧ»á¿Æ¼¼Ò»µÈ½±£º»ùÓÚÏû°Y»¯ðö·öÕý·¨Ñз¢ÏµÁп¹Ö×ÁöÖ²ÎïÒ©éÏãÏ©¼°²úÒµ»¯¼¼Êõ£¬µÚÒ»Íê³ÉÈË
13.Öйúҽѧ¿ÆѧԺѧ²¿Î¯Ô±¡¢¹úÎñÔºÌØÊâ½òÌùר¼Ò¡¢¹ú¼Ò᪻ÆѧÕß¡¢Õã½Ê¡Ìؼ¶×¨¼Ò¡¢Ó¢¹ú»Ê¼Ò»¯Ñ§»á»áÊ¿¡¢Õã½Ê¡Í»³ö¹±Ï×ÖÐÇàÄêר¼Ò¡¢Õã½Ê¡¡°151¡±È˲ŵ¼Ê¦¡¢º¼ÖÝÊÐÐÂÊÀ¼Í¡°131¡±ÓÅÐãÖÐÇàÄêÈ˲ŵÚÒ»²ã´Î¡¢2007-2008Äê¶Èº¼ÖÝÊÐÏȽø¿Æ¼¼¹¤×÷Õß¡¢º¼ÖÝÊнÌÓý¾ÖϵͳÓÅÐã½Ìʦ¡¢º¼ÖÝÊпƼ¼´´ÐÂÌرð¹±Ï×½±¡¢º¼ÖÝʦ·¶´óѧͳһսÏß¡°Í¬ÐĽ±¡±µÈ
......